Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Avata Biosciences
Deal Size : $95.0 million
Deal Type : Licensing Agreement
Avata Signs Co-Development and Licensing Agreement with Oceanus
Details : The agreement grants for the exclusive rights to AVAT-021 and AVAT-022 in Japan and Asia, except in China and India for neurological conditions.
Product Name : AVAT-021
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 17, 2025
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Avata Biosciences
Deal Size : $95.0 million
Deal Type : Licensing Agreement
Reset All
